1. Academic Validation
  2. Non‑invasive monitoring of cisplatin and erlotinib efficacy against lung cancer in orthotopic SCID mouse models by small animal FDG‑PET/CT and CT

Non‑invasive monitoring of cisplatin and erlotinib efficacy against lung cancer in orthotopic SCID mouse models by small animal FDG‑PET/CT and CT

  • Oncol Rep. 2019 Jan;41(1):447-454. doi: 10.3892/or.2018.6818.
Tamaki Otani 1 Kazuya Kondo 2 Hiromitsu Takizawa 3 Koichiro Kajiura 3 Haruhiko Fujino 3 Hideki Otsuka 4 Hirokazu Miyoshi 1
Affiliations

Affiliations

  • 1 Radioisotope Research Center, Tokushima University Graduate School, Tokushima City, Tokushima 770‑8503, Japan.
  • 2 Department of Oncological Medical Services, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima City, Tokushima 770‑8503, Japan.
  • 3 Department of Thoracic, Endocrine Surgery and Oncology, Institute of Biomedical Sciences, Tokushima City, Tokushima 770‑8503, Japan.
  • 4 Department of Medical Imaging/Nuclear Medicine, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima City, Tokushima 770‑8503, Japan.
Abstract

We established patient‑like models of lung Cancer metastasis by orthotopically implanting human non‑small cell lung Cancer cell lines into SCID mice. We evaluated the utilities of small‑animal computed tomography (CT) and positron‑emission tomography‑computed tomography (PET/CT) in these models to non‑invasively and repeatedly monitor the Anticancer effects of cisplatin and erlotinib. We orthotopically implanted three non‑small cell lung Cancer cell lines, A549, FT821 and PC‑9, into SCID mice. These mice were then divided into three groups: Control, cis‑diamminedichloroplatinum (II) (CDDP) (7‑mg/kg CDDP, single administration intraperitoneally), and erlotinib (25 mg/kg erlotinib/day, oral administration 5 days/week). After treatment initiation, we repeatedly performed PET/CT and CT measurements and assessed Anticancer effects based on tumor volumes and FDG uptake. A549 tumors were not affected by CDDP or erlotinib. FT821 tumors were highly responsive to CDDP. PC‑9 tumors, which have an epidermal growth factor receptor mutation, were highly responsive to erlotinib. Histological results and metastatic rates correlated with the Anticancer effects shown by CT. In our orthotopic SCID mouse Lung Cancer Models, 18FDG‑PET/CT and CT imaging non‑invasively and repeatedly monitored the efficacies of cisplatin and erlotinib against not only implanted tumors, but also mediastinal lymph node metastases.

Figures
Products